Coleman DT - Search Results

1

Isothiocyanatostilbenes as novel c-Met inhibitors.

Gray AL, Coleman DT, Castore RF, Mohyeldin MM, El Sayed KA, Cardelli JA. Gray AL, et al. Among authors: coleman dt. Oncotarget. 2015 Dec 1;6(38):41180-93. doi: 10.18632/oncotarget.5748. Oncotarget. 2015. PMID: 26543230 Free PMC article.

2

Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation.

Coleman DT, Bigelow R, Cardelli JA. Coleman DT, et al. Mol Cancer Ther. 2009 Jan;8(1):214-24. doi: 10.1158/1535-7163.MCT-08-0722. Mol Cancer Ther. 2009. PMID: 19139131 Free PMC article.

3

The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.

Milligan SA, Burke P, Coleman DT, Bigelow RL, Steffan JJ, Carroll JL, Williams BJ, Cardelli JA. Milligan SA, et al. Among authors: coleman dt. Clin Cancer Res. 2009 Aug 1;15(15):4885-94. doi: 10.1158/1078-0432.CCR-09-0109. Epub 2009 Jul 28. Clin Cancer Res. 2009. PMID: 19638461 Free PMC article.

4

The HGF-met signaling axis: emerging themes and targets of inhibition.

Steffan JJ, Coleman DT, Cardelli JA. Steffan JJ, et al. Among authors: coleman dt. Curr Protein Pept Sci. 2011 Feb;12(1):12-22. doi: 10.2174/138920311795659425. Curr Protein Pept Sci. 2011. PMID: 21190524 Review.

5

Repurposed drug screen identifies cardiac glycosides as inhibitors of TGF-β-induced cancer-associated fibroblast differentiation.

Coleman DT, Gray AL, Stephens CA, Scott ML, Cardelli JA. Coleman DT, et al. Oncotarget. 2016 May 31;7(22):32200-9. doi: 10.18632/oncotarget.8609. Oncotarget. 2016. PMID: 27058757 Free PMC article.

6

Palmitoylation regulates the intracellular trafficking and stability of c-Met.

Coleman DT, Gray AL, Kridel SJ, Cardelli JA. Coleman DT, et al. Oncotarget. 2016 May 31;7(22):32664-77. doi: 10.18632/oncotarget.8706. Oncotarget. 2016. PMID: 27081699 Free PMC article.

7

The Arf-like GTPase Arl8b is essential for three-dimensional invasive growth of prostate cancer in vitro and xenograft formation and growth in vivo.

Dykes SS, Gray AL, Coleman DT, Saxena M, Stephens CA, Carroll JL, Pruitt K, Cardelli JA. Dykes SS, et al. Among authors: coleman dt. Oncotarget. 2016 May 24;7(21):31037-52. doi: 10.18632/oncotarget.8832. Oncotarget. 2016. PMID: 27105540 Free PMC article.

8

Monocarboxylate transporter 1 contributes to growth factor-induced tumor cell migration independent of transporter activity.

Gray AL, Coleman DT, Shi R, Cardelli JA. Gray AL, et al. Among authors: coleman dt. Oncotarget. 2016 May 31;7(22):32695-706. doi: 10.18632/oncotarget.9016. Oncotarget. 2016. PMID: 27127175 Free PMC article.

9

The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells.

Duhon D, Bigelow RL, Coleman DT, Steffan JJ, Yu C, Langston W, Kevil CG, Cardelli JA. Duhon D, et al. Among authors: coleman dt. Mol Carcinog. 2010 Aug;49(8):739-49. doi: 10.1002/mc.20649. Mol Carcinog. 2010. PMID: 20623641

10

The polyphenols (-)-epigallocatechin-3-gallate and luteolin synergistically inhibit TGF-β-induced myofibroblast phenotypes through RhoA and ERK inhibition.

Gray AL, Stephens CA, Bigelow RL, Coleman DT, Cardelli JA. Gray AL, et al. Among authors: coleman dt. PLoS One. 2014 Oct 1;9(10):e109208. doi: 10.1371/journal.pone.0109208. eCollection 2014. PLoS One. 2014. PMID: 25272043 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page